Clinical trials sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase breakdown

Conditions studied

Recruiting trials led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

• A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
  NCT05953350 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
  NCT04803539 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
  NCT04501523 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
  NCT06925516 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients
  NCT07377279 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
  NCT05760612 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
  NCT06278870 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
  NCT05466786 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
  NCT07037199 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
  NCT07358182 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Endoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC
  NCT07548762 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
  NCT04646759 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• Large Language Models Assist in Tumor MDT
  NCT07504367 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 33 Years · Sex: All (male and female) · 6 locations
• Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis
  NCT06301373 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 5 locations
• Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
  NCT06319157 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
  NCT07066280 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
  NCT07095023 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
  NCT05159193 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT06121570 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT06121557 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
  NCT06892093 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location
• Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
  NCT06255392 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer
  NCT04069884 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
  NCT06313463 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT05981014 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
  NCT06541626 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• TCR-T Cell Therapy on Advanced Solid Tumors
  NCT05438667 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
  NCT06851299 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
  NCT06641544 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many trials is Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University recruiting for?

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 29 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.